Selenium status indices, laboratory data, and selected biochemical parameters in end-stage renal disease patients

Zagrodzki, Paweł; Bartoń, H.; Walas, Stanisław; Fołta, Maria; Stompór, Tomasz; Janusz-Grzybowska, Eve; Drożdż, Maciej; Sułowicz, Władysław

doi:10.1007/bf02685916

Cited by 18 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, a study of the influence of glucose in the dialysate on oxidative stress intensity, glutathione activity, and plasma Se in HPs [5] found plasma Se concentrations to be increased by hemodialysis. The reduced Se body status in HPs has been related to a higher susceptibility to diseases such as congestive cardiomyopathy and CV diseases [28,29].…”

Section: Resultsmentioning

confidence: 99%

Altered Serum Selenium and Uric Acid Levels and Dyslipidemia in Hemodialysis Patients Could be Associated with Enhanced Cardiovascular Risk

Moral

Agil

Navarro-Alarcón

et al. 2011

Biol Trace Elem Res

View full text Add to dashboard Cite

In the present study, the first objective was to follow up serum selenium (Se) concentrations in 117 hemodialysis patients (HPs) during a 2-year longitudinal study, relating concentrations to biochemical indexes (n = 6; namely lipoprotein profile, uric acid, and total protein levels). It was also evaluated whether the disease is associated with an enhanced cardiovascular risk. A healthy control group (n = 50) was also studied. Mean serum Se levels were significantly lower in HPs than in the controls (p = 0.002); mean levels significantly increased from the first to third blood sampling (p < 0.001). HPs showed a marked dyslipidemia, with a significant reduction in total cholesterol, low-density lipoprotein, and high-density lipoprotein cholesterol levels and a significant increase in triglyceride levels (p < 0.001). HPs showed a marked hyperuricemia (p < 0.001). Serum selenium levels in HPs were correlated negatively with uric acid levels (inflammation biomarker; p < 0.01). In HPs, serum Se levels are reduced due to their disease (chronic renal failure). Serum Se levels rose until the third blood sampling. The marked dyslipidemia and hyperuricemia found in HPs and the negative correlation between the serum Se and uric acid levels in these patients could imply an enhanced cardiovascular risk.

show abstract

Section: Resultsmentioning

confidence: 99%

Altered Serum Selenium and Uric Acid Levels and Dyslipidemia in Hemodialysis Patients Could be Associated with Enhanced Cardiovascular Risk

Moral

Agil

Navarro-Alarcón

et al. 2011

Biol Trace Elem Res

View full text Add to dashboard Cite

show abstract

“…Dializált betegekben csökkent a szérum, a vörösvértest és fehér-vérsejt szeléntartalma [32,33,34], bár normális szé-rumszintet is kimutattak dializált betegekben [20,26]. A szelénszint csökkenése oka lehet a kialakuló congestiv cardiomyopathiának, az akcelerált atherosclerosisnak, a vázizomzat myopathiájának, az anaemiának, a fokozott tumorkockázatnak, az arthritisnek, a termé-ketlenségnek, a cataracta kialakulásának, a kognitív diszfunkciónak és a károsodott immunfunkciónak krónikus vesebetegségben, illetve veseelégtelenségben szenvedő betegekben [21,26,28,34,35,36,37,38].…”

Section: Szelénmetabolizmus Krónikus Vesebetegségbenunclassified

Importance of selenium homeostasis in chronic and end-stage kidney diseases

Kiss

2013

Orvosi Hetilap

View full text Add to dashboard Cite

A szelén az emberi szervezet számára nélkülözhetetlen nyomelem, jelentős antioxidáns hatással rendelkezik. A szelénhiány és -többlet egyaránt károsan befolyásolja a szervezet működését. A szelénhiány és az akut vagy krónikus vesebetegség, illetve a szövődmények kapcsolata kevésbé intenzíven kutatott terület. Az eddigi eredmények alapján ismertté vált, hogy a szelénhiány és a veseelégtelenség fokozza a koszorúér-betegség okozta és az összhalálozás kockázatát. További megfi gyelések szerint a szelénhiány az immunrendszer működési zavarán keresztül fokozza az infekció okozta halálozás kockázatát hemodializált betegekben. Jelenleg azonban nincs tudomásunk arról, hogy a szelén-háztartás zavara, elsősorban a szelén hiánya, krónikus vesebetegséget vagy veseelégtelenséget okozna. Ugyanakkor elégséges ismerettel rendelkezünk arról, hogy a fehérjevesztés és a vesepótló kezelés csökkentheti a szelénszintet. A szelénhiány és a krónikus vesebetegség kapcsolatával foglalkozó vizsgálatok gyakran ellentmondó eredményei ellenére úgy tűnik, hogy súlyos vagy végállapotú, vesepótló kezelésre szoruló dializált betegekben a szelénszupplemen-táció számos esetben kedvező lehet. Orv. Hetil., 2013, 154, 1641-1647. Kulcsszavak: szelénhiány, cardiovascularis kockázat, krónikus vesebetegség, vesepótló kezelés Importance of selenium homeostasis in chronic and end-stage kidney diseasesSelenium is an essential trace element for the human body with a signifi cant antioxidant effect. Selenium defi ciency and excess are both detrimental for proper functioning of the human body. The possible association between selenium defi ciency and acute or chronic renal disease, along with their complications has been less intensively investigated, however, there are fi rm data showing that selenium defi ciency and renal failure increase the risk of both coronary artery disease and total mortality. Further studies revealed that selenium defi ciency increases the risk of death due to infection in patients treated with hemodialysis through dysfunction of the immune system. However, there are no data whether the imbalance of selenium metabolism, especially selenium defi ciency, could cause chronic kidney disease or renal failure. As far as results of selenium measurements, there is convincing evidence that protein loss and renal replacement treatment reduce serum selenium levels. Despite some contradictory results obtained from various studies regarding selenium defi ciency in chronic kidney diseases, it seems that selenium supplementation may be benefi cial in many patients with severe or end-stage kidney disease including those treated with dialysis.Keywords: selenium defi ciency, cardiovascular risk, chronic renal disease, hemodialysis Kiss, I. (2013)

show abstract

“…The kidney accumulates the highest amounts of Se and is the major source of plasma GPx (Adamowicz et al, 2002). The plasma concentrations of Se and GPx activities are significantly lower in dialysis patients than in healthy controls (Zagrodzki et al, 2007;Tonelli et al, 2009;Pakfetrat et al, 2010;Fujishima et al, 2011a). Reduced intake of Se lowers the blood Se status of dialysis patients (Andrew et al, 2008).…”

Section: Seleniummentioning

confidence: 99%

“…Treatment with yeast-Se (900 µg of Se/week) caused an increase in Se concentrations and erythrocyte GPx activity (Zachara et al, 2001). On the other hand, increased plasma Se is positively associated with indices of erythropoiesis and nutritional status (Zagrodzki et al, 2007). Significantly increased Se concentrations were seen after 4-months of recombinant human erythropoietin (rHuEpo) treatment (Celiker et al, 2001).…”

Section: Seleniummentioning

confidence: 99%